Published in
American Society of Hematology, Blood, 24(125), p. 3679-3687, 2015
DOI: 10.1182/blood-2015-03-635169
Links
- ORCID
- ORCID
- ORCID
- ORCID
- ORCID
- American Society of Hematology | PDF
- ORCID
- [europepmc.org] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [www.researchgate.net] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
Tools
Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing
Journal article published in 2015 by
David M. Kurtz 
,
Michael R. Green ,
Scott V. Bratman,
Florian Scherer,
Chih Long Liu,
Christian A. Kunder ,
Kazuhiro Takahashi,
Cynthia Glover,
Colm Keane ,
Shingo Kihira,
Brendan Visser,
Jason Callahan,
Katherine A. Kong,
Malek Faham,
Karen S. Corbelli
and other authors.
,
Michael R. Green ,
Scott V. Bratman,
Florian Scherer,
Chih Long Liu,
Christian A. Kunder ,
Kazuhiro Takahashi,
Cynthia Glover,
Colm Keane ,
Shingo Kihira,
Brendan Visser,
Jason Callahan,
Katherine A. Kong,
Malek Faham,
Karen S. Corbelli
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Key Points DLBCL can be detected in the blood by immunoglobulin high-throughput sequencing (Ig-HTS) with high specificity. Although DLBCL can be detected in leukocytes or plasma by Ig-HTS, plasma has greater sensitivity and more accurately reflects disease.